Phase II Study of Ibrutinib With or Without Bortezomib and Dexamethasone for the Treatment of Patients With Relapsed/Refractory Immunoglobulin Light Chain Amyloidosis
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Bortezomib (Primary) ; Ibrutinib (Primary) ; Dexamethasone
- Indications Amyloidosis
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 28 Feb 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 05 Feb 2018 Planned initiation date changed from 15 Dec 2017 to 15 Mar 2018.